stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Net income
Veracyte, Inc.'s net income for fiscal 2025 was $66.4M, up 174.9% from $24.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $126.8M. Over the past ten years it has ranged from −$75.6M (fiscal 2021) to $66.4M (fiscal 2025) — the current reading is the highest in ten years. Veracyte, Inc. ranks 16th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $66.4M | 174.89% |
| FY2024 | $24.1M | — |
| FY2023 | −$74.4M | — |
| FY2022 | −$36.6M | — |
| FY2021 | −$75.6M | — |
| FY2020 | −$34.9M | — |
| FY2019 | −$12.6M | — |
| FY2018 | −$23.0M | — |
| FY2017 | −$31.0M | — |
| FY2016 | −$31.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $31.5M | 23.59% |
| Jun 2026 | $25.5M | (11.21%) |
| Mar 2026 | $28.7M | (30.24%) |
| Dec 2025 | $41.1M | 115.02% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SHC Sotera Health Company compare | $173.5M |
| CDNA CareDx, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. | $126.8M |
| BLLN BillionToOne, Inc. compare | $49.4M |
| RDNT RadNet, Inc. compare | $19.3M |
| NEO NeoGenomics, Inc. compare | −$32.3M |
| ADPT Adaptive Biotechnologies Corporation compare | −$70.7M |
| WGS GeneDx Holdings Corp. compare | −$106.4M |
| GRAL GRAIL, Inc. compare | −$406.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on VCYT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement